

# Jinlin Hou

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1547804/jinlin-hou-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124  
papers

2,388  
citations

26  
h-index

44  
g-index

142  
ext. papers

3,316  
ext. citations

7  
avg, IF

5.05  
L-index

#	Paper	IF	Citations
124	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 700-710	13.4	236
123	Therapeutic strategies for hepatitis B virus infection: towards a cure. <i>Nature Reviews Drug Discovery</i> , <b>2019</b> , 18, 827-844	64.1	183
122	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , <b>2017</b> , 5, 297-318	5.2	136
121	Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 132-136	6.9	132
120	qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 260-269	13.4	93
119	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. <i>Gut</i> , <b>2016</b> , 65, 313-20	19.2	85
118	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. <i>Hepatology</i> , <b>2014</b> , 59, 1283-92	11.2	62
117	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 776-787	18.8	51
116	Caffeine reduces hepatic lipid accumulation through regulation of lipogenesis and ER stress in zebrafish larvae. <i>Journal of Biomedical Science</i> , <b>2015</b> , 22, 105	13.3	50
115	Hepatitis C virus genotypes and subtypes circulating in Mainland China. <i>Emerging Microbes and Infections</i> , <b>2017</b> , 6, e95	18.9	46
114	HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. <i>Journal of Clinical and Translational Hepatology</i> , <b>2018</b> , 6, 25-34	5.2	45
113	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 719-727.e7	6.9	45
112	Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 581-589	7	43
111	High fat plus high cholesterol diet lead to hepatic steatosis in zebrafish larvae: a novel model for screening anti-hepatic steatosis drugs. <i>Nutrition and Metabolism</i> , <b>2015</b> , 12, 42	4.6	42
110	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1368-1378	13.4	41
109	Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. <i>EBioMedicine</i> , <b>2018</b> , 36, 151-158	8.8	39
108	Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis. <i>Hepatology</i> , <b>2015</b> , 61, 1998-2007	11.2	36

107	ECM1 Prevents Activation of Transforming Growth Factor $\beta$ Hepatic Stellate Cells, and Fibrogenesis in Mice. <i>Gastroenterology</i> , <b>2019</b> , 157, 1352-1367.e13	13.3	35
106	Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 182-191.e1	6.9	35
105	Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study. <i>Virologica Sinica</i> , <b>2020</b> , 35, 820-829	6.4	32
104	Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients. <i>Hepatology</i> , <b>2021</b> , 73, 41-52	11.2	32
103	Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 16498-16506	3.3	31
102	CXCL13-mediated recruitment of intrahepatic CXCR5CD8 T cells favors viral control in chronic HBV infection. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 420-430	13.4	31
101	Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: A 2-year prospective study. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 296-305	3.4	30
100	Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1929-1936.e1	6.9	28
99	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 674-682	13.4	27
98	Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2020</b> , 222, 611-618	7	26
97	Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal Hypertension. <i>Radiology</i> , <b>2019</b> , 290, 370-377	20.5	23
96	Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 584-592	13.4	23
95	Epigenetically regulated miR-449a enhances hepatitis B virus replication by targeting cAMP-responsive element binding protein 5 and modulating hepatocytes phenotype. <i>Scientific Reports</i> , <b>2016</b> , 6, 25389	4.9	22
94	Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 748-55	4	21
93	Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil-mediated complement activation. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 733-743	13.4	21
92	The SMAC Mimetic APG-1387 Sensitizes Immune-Mediated Cell Apoptosis in Hepatocellular Carcinoma. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1298	5.6	18
91	Mannan binding lectin attenuates double-stranded RNA-mediated TLR3 activation and innate immunity. <i>FEBS Letters</i> , <b>2014</b> , 588, 866-72	3.8	17
90	Role of interleukin-21 in HBV infection: friend or foe?. <i>Cellular and Molecular Immunology</i> , <b>2015</b> , 12, 303-314	5.4	16

89	STAT4: an immunoregulator contributing to diverse human diseases. <i>International Journal of Biological Sciences</i> , <b>2020</b> , 16, 1575-1585	11.2	16
88	Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144425	3.7	16
87	Hepatitis B virus genotype B and mutations in basal core promoter and pre-core/core genes associated with acute-on-chronic liver failure: a multicenter cross-sectional study in China. <i>Hepatology International</i> , <b>2014</b> , 8, 508-16	8.8	16
86	Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. <i>Hepatology International</i> , <b>2019</b> , 13, 573-586	8.8	15
85	Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. <i>Antiviral Research</i> , <b>2015</b> , 118, 10-9	10.8	15
84	Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 839-849	18.8	15
83	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. <i>Hepatology Research</i> , <b>2018</b> , 48, E213-E221	5.1	14
82	Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1173	8.4	14
81	Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. <i>Infection, Genetics and Evolution</i> , <b>2015</b> , 33, 261-8	4.5	14
80	Pre-Activation of Toll-Like Receptor 2 Enhances CD8 T-Cell Responses and Accelerates Hepatitis B Virus Clearance in the Mouse Models. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1495	8.4	13
79	Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. <i>Scientific Reports</i> , <b>2015</b> , 5, 17123	4.9	13
78	Biogenesis and molecular characteristics of serum hepatitis B virus RNA. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008045	10.4	13
77	Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN- $\alpha$ antiviral therapy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2017</b> , 41, 386-398	2.4	12
76	Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis: An analysis of data from CHES-1601 trial. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	12
75	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , <b>2020</b> , 69, 1116-1126	19.2	12
74	Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 692-700	6.1	11
73	Deep Convolutional Neural Network-Aided Detection of Portal Hypertension in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2998-3007.e5	6.9	11
72	Improving survival of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis. <i>Scientific Reports</i> , <b>2018</b> , 8, 876	4.9	11

71	Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 459-465	4	11
70	Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 323	8.4	11
69	Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy. <i>Journal of Translational Medicine</i> , <b>2017</b> , 15, 64	8.5	10
68	Transforming growth factor $\beta$ -activated kinase 1 transcriptionally suppresses hepatitis B virus replication. <i>Scientific Reports</i> , <b>2017</b> , 7, 39901	4.9	10
67	Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. <i>Hepatology International</i> , <b>2019</b> , 13, 260-269	8.8	10
66	Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients. <i>Hepatology Research</i> , <b>2018</b> , 48, 134-143	5.1	10
65	A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. <i>Value in Health Regional Issues</i> , <b>2013</b> , 2, 48-56	1.6	10
64	Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 659-666	4	10
63	A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01). <i>Journal of Clinical and Translational Hepatology</i> , <b>2020</b> , 8, 1-8	5.2	10
62	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. <i>Scientific Reports</i> , <b>2016</b> , 6, 37498	4.9	10
61	Interleukin 21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)-Specific CD8+ T Cells in Chronic HBV Infection. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 750-759	7	10
60	A hepatitis B-free generation in China: from dream to reality. <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 1103-1105	25.5	9
59	Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 1043-1051	3.4	9
58	Inflammation-induced overexpression of microRNA-223-3p regulates odontoblastic differentiation of human dental pulp stem cells by targeting SMAD3. <i>International Endodontic Journal</i> , <b>2019</b> , 52, 491-503	5.4	9
57	Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data. <i>Antiviral Therapy</i> , <b>2019</b> , 24, 133-140	1.6	8
56	Elevated D-dimer is associated with increased 28-day mortality in acute-on-chronic liver failure in China: a retrospective study. <i>BMC Gastroenterology</i> , <b>2019</b> , 19, 20	3	8
55	TCR $\alpha$ <sup>+</sup> CD4 <sup>-</sup> CD8 <sup>-</sup> T cells suppress the CD8 <sup>+</sup> T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B. <i>PLoS ONE</i> , <b>2014</b> , 9, e88475	3.7	8
54	Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 197	21	8

53	Impacts of cigarette smoking on liver fibrosis and its regression under therapy in male patients with chronic hepatitis B. <i>Liver International</i> , <b>2019</b> , 39, 1428-1436	7.9	7
52	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1969-1979	11.6	7
51	Tri-typing of hepatitis B-related acute-on-chronic liver failure defined by the World Gastroenterology Organization. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 208-214	11.6	7
50	Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 196-204.e8	6.9	7
49	Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis. <i>International Journal of Biological Markers</i> , <b>2018</b> , 33, 266-274	2.8	6
48	Loss of HBsAg and antiviral treatment: from basics to clinical significance. <i>Hepatology International</i> , <b>2014</b> , 8, 39-54	8.8	6
47	Dental nerves: a neglected mediator of pulpitis. <i>International Endodontic Journal</i> , <b>2021</b> , 54, 85-99	5.4	6
46	Improvements in the management of chronic hepatitis B virus infection. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 1153-1166	4.2	6
45	Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection?. <i>Virologica Sinica</i> , <b>2018</b> , 33, 459-461	6.4	6
44	The predictive value of baseline hepatic venous pressure gradient for variceal rebleeding in cirrhotic patients receiving secondary prevention. <i>Annals of Translational Medicine</i> , <b>2020</b> , 8, 91	3.2	5
43	Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1142	8.4	5
42	Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 598-607	3.4	5
41	IL-21 receptor signaling is essential for control of hepatocellular carcinoma growth and immunological memory for tumor challenge. <i>Oncotarget</i> , <b>2018</b> , 7, e1500673	7.2	5
40	Systematic quantification of histological patterns shows accuracy in reflecting cirrhotic remodeling. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1631-1639	4	4
39	Influence of Gender and Reproductive Factors on Liver Fibrosis in Patients With Chronic Hepatitis B Infection. <i>Clinical and Translational Gastroenterology</i> , <b>2019</b> , 10, e00085	4.2	4
38	Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. <i>BMC Gastroenterology</i> , <b>2019</b> , 19, 65	3	3
37	Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2020</b> , 20, 403	4.8	3
36	A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFN therapy in Chinese HBeAg-positive chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 469-478	6.1	3

35	Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 1469-1476	7	3
34	Alterations in gut microbiota and elevated serum bilirubin in primary biliary cholangitis patients treated with ursodeoxycholic acid. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , e13714	4.6	3
33	Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients. <i>Antiviral Research</i> , <b>2021</b> , 189, 105037	10.8	3
32	Targeting cIAPs attenuates CCl-induced liver fibrosis by increasing MMP9 expression derived from neutrophils.. <i>Life Sciences</i> , <b>2021</b> , 289, 120235	6.8	2
31	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , <b>2019</b> , 7, 322-328	5.2	2
30	China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. <i>Scandinavian Journal of Public Health</i> , <b>2020</b> , 48, 233-239	3	2
29	Detachable string magnetically controlled capsule endoscopy for detecting high-risk varices in compensated advanced chronic liver disease (CHESS1801): A prospective multicenter study. <i>The Lancet Regional Health - Western Pacific</i> , <b>2021</b> , 6, 100072	5	2
28	Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 709-714	6.1	2
27	Fine Mapping of the MHC Region Identifies Novel Variants Associated with HBV-Related Hepatocellular Carcinoma in Han Chinese. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 951-961	5.3	2
26	Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy.. <i>Journal of Infectious Diseases</i> , <b>2021</b> ,	7	2
25	The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response. <i>Infection, Genetics and Evolution</i> , <b>2017</b> , 49, 116-121	4.5	1
24	Combination Therapy With Tenofovir and Peginterferon May Not Be Translated Into Current Clinical Practice. <i>Gastroenterology</i> , <b>2016</b> , 150, 1253-1254	13.3	1
23	Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study. <i>Journal of Cancer</i> , <b>2018</b> , 9, 1385-1393	4.5	1
22	A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2021</b> , 14, 1505-1515	2.1	1
21	Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. <i>Journal of Medical Virology</i> , <b>2020</b> , 92, 1206-1213	19.7	1
20	Reply to: "External validation of aMAP risk score in patients with chronic hepatitis C genotype 4 and cirrhosis who achieved SVR following DAAs". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 996-997	13.4	1
19	Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. <i>Advances in Therapy</i> , <b>2021</b> , 38, 3409-3426	4.1	1
18	Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 329-338	6.1	1

17	Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 43-51	1.6	1
16	Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1134-1149	6.1	1
15	A Genetic Variant of PPP1CB Influences Risk of Hepatitis B Virus-Related Hepatocellular Carcinoma in Han Chinese: A Pathway Based Analysis. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 1055-1064	5.3	1
14	The effect of Malononitrilamides (FK778) on phenotypic properties of human peripheral dendritic cells. <i>Transplantation Proceedings</i> , <b>2009</b> , 41, 1859-61	1.1	0
13	Review article: biomarkers for predicting nucleos(t)ide analogues discontinuation and HBV recurrence after drug withdrawal in chronic hepatitis B patients.. <i>Hepatology Research</i> , <b>2022</b> ,	5.1	0
12	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2147-2148	6.9	0
11	High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 649197	8.4	0
10	Shifting demographics and comorbidity burden in adult Chinese urban patients with chronic hepatitis B, 2013 and 2016. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 647-657	2.1	0
9	Pan-Cancer Analysis Identified as a Potential Biomarker for Multiple Tumor Types. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 693651	5.6	0
8	Prevalence of Dual-Positivity for Both Hepatitis B e Antigen and Hepatitis B e Antibody Among Hospitalized Patients with Chronic Hepatitis B Virus Infection. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 5759-5770	2.3	0
7	Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 813275	5.3	0
6	An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression.. <i>Nature Communications</i> , <b>2022</b> , 13, 1232	17.4	0
5	Alterations in the Gut Microbiota and Hepatitis-B-Virus Infection in Southern Chinese Patients With Coexisting Non-Alcoholic Fatty Liver Disease and Type-2 Diabetes Mellitus.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 805029	4.9	0
4	Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>JAMA Oncology</i> , <b>2019</b> , 5, 915	13.4	
3	Letter: cross-linkage between bacterial taxonomy and gene functions-a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1505-1507	6.1	
2	Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. <i>Journal of Clinical and Translational Hepatology</i> , <b>2020</b> , 8, 255-261	5.2	
1	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 756-757	6.9	